Bellevue Global Life Science Investors LLC - Feb 9, 2023 Form 3 Insider Report for Bellevue Life Sciences Acquisition Corp. (BLAC)

Role
10%+ Owner
Signature
By: Bellevue Capital Management LLC, Its Manager /s/ Kuk Hyoun Hwang, Managing Member
Stock symbol
BLAC
Transactions as of
Feb 9, 2023
Transactions value $
$0
Form type
3
Date filed
2/9/2023, 03:49 PM
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BLAC Common Stock 1.73M Feb 9, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3 is being filed by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor"). Kuk Hyoun Hwang, the Issuer's chief executive officer and director, is the founder and managing partner of Bellevue Capital Management LLC ("Bellevue Capital"), the general partner of our sponsor, and has voting and dispositive power over the shares.
F2 Includes up to 225,000 shares subject to forfeiture depending on the extent to which the underwriter's over allotment is exercised, if at all.
F3 Includes 680,000 shares of common stock held by the Sponsor which, pursuant to a convertible promissory note in the principal amount of $3,400,000 between the Sponsor and BCM Europe AG, a wholly-owned subsidiary of Bellevue Capital, the Sponsor, at its election or the election of BCM Europe AG on or after the initial public offering the common stock, can transfer the 680,000 shares to BCM Europe AG in satisfaction of the note.